Will qbio stock price drop/Fall/Rise/Fall?
11 days ago. QBIO was $2.28 two years ago when Investor69 "dug-in" for life changing roi, you should review some of his old posts promoting this stock, stunning energy expended. $10,000.00 ...
Is Q BioMed Inc (qbio) stock a good investment?
Q BIOMED INC (QBIO) stock forecast and price target. ... Stocks fall, tech shares lag for a second straight day after more hawkish Fed commentary: Nasdaq declines by 2.2%.
How often do you update the qbio projections?
Our Ai stock analyst implies that there will be a negative trend in the future and the QBIO shares are not a good investment for making money. Since this share has a negative outlook we recommend looking for other projects instead to build a portfolio.
Will qbio’s strontium89 sales double in Q4?
Apr 14, 2022 · The stock lies in the middle of a very wide and falling trend in the short term and further fall within the trend is signaled. Given the current short-term trend, the stock is expected to fall -52.52% during the next 3 months and, with a 90% probability hold a price between $0.0680 and $0.12 at the end of this 3-month period. Do note, that if the stock price manages to stay at …
"Should I invest in Q BioMed stock?" "Should I trade "QBIO" stock today?"
According to our live Forecast System, Q BioMed Inc stock is a bad long-term (1-year) investment *.
What is the Q BioMed stock price / share price today?
The Q BioMed stock price is 0.433 USD today.
Will QBIO stock price drop / fall?
Yes. The Q BioMed stock price may drop from 0.433 USD to 0.00126 USD...
Will QBIO stock price grow / rise / go up?
No. See above .
Will QBIO stock price crash?
According to our analysis, this can happen.
Will Q BioMed stock price hit 1 USD price in a year?
Not within a year. See above .
Will Q BioMed stock price hit 5 USD price in a year?
Not within a year. See above .
Will Q BioMed stock price hit 10 USD price in a year?
Not within a year. See above .
Signals & Forecast
Support, Risk & Stop-loss
A buy signal was issued from a pivot bottom point on Thursday, September 09, 2021, and so far it has risen 15.67%. Further rise is indicated until a new top pivot has been found. Furthermore, there is a buy signal from the 3 months Moving Average Convergence Divergence (MACD). Q BioMed Inc.
Is Q BioMed Inc. stock A Buy?
On the downside, the stock finds support just below today's level from accumulated volume at $0.73 and $0.72. There is natural risk involved when a stock is testing a support level, since if this is broken, the stock then may fall to the next support level. In this case, Q BioMed Inc. finds support just below today's level at $0.73.
Who owns Q Biomed?
Q BioMed Inc. holds several negative signals and we believe that it will still perform weakly in the next couple of days or weeks. We, therefore, hold a negative evaluation of this stock. We have upgraded our analysis conclusion for this stock since the last evaluation from a Strong Sell to a Sell candidate.
What is Q Biomed?
Q BioMed Inc. (OTCQB: QBIO), announced today that it has signed a securities purchase agreement ("Transaction") with Aedesius Holdings Ltd (AedesiusOne), a privately owned United Kingdom based healthcare and technology aggregator. AedesiusOne is run by Geoffrey Fatzinger, our Global Head of Regulatory Affairs. The agreement gives AedesiusOne the opportunity to buy approximately 43% of the outstanding QBIO shares for an aggregate of $30,000,000. The Transaction is structured as an initial investment of $5,000,000 with an additional $15,000,000 by September 30, 2021 with 50% warrant coverage allowing an additional $10,000,000 investment within 120 days. The Unit Price is set at $1.25 per share, a 31% premium to yesterday's closing price. The investor is expected to ultimately take a seat on the Board.
What is Uttroside B?
(OTCQB: QBIO), announced today that the U.S. Food and Drug Administration's Office of Orphan Products Development has granted Orphan Drug Designation to Uttroside-B, a small molecule chemotherapeutic for the treatment of hepatocellular carcinoma (HCC), the most common form of liver cancer. In preclinical studies, Uttroside-B was up ...
Is Strontium Chloride Sr 89 FSS?
The patent titled "Uttroside-B and Derivatives Thereof as Therapeutics for Hepatocellular Carcinoma" is a Method Of Use patent that covers the use of Uttroside-B for the treatment of hepatocellular carcinoma (HCC), the most common form of liver cancer.
What stocks does MarketBeat like better than Q BioMed?
(OTCQB: QBIO), a commercial stage biotech company, announced today that it has signed an agreement for Strontium89 (Strontium Chloride Sr-89 Injection, USP) to be included on the Federal Supply Schedule ("FSS"). The agreement provides U.S. veterans and other federal government agencies access to Strontium89 for eligible patients. The final FSS contract is effective March 1, 2021 and has a five-year term. The FSS contract will extend access to Strontium89 to over nine million VA beneficiaries and others within the federal system.
Are investors shorting Q BioMed?
Wall Street analysts have given Q BioMed a "N/A" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Q BioMed wasn't one of them.
When is Q BioMed's next earnings date?
Q BioMed saw a increase in short interest in August. As of August 13th, there was short interest totaling 40,800 shares, an increase of 204.5% from the July 29th total of 13,400 shares. Based on an average daily trading volume, of 107,500 shares, the short-interest ratio is presently 0.4 days.#N#View Q BioMed's Short Interest.
How were Q BioMed's earnings last quarter?
Q BioMed is scheduled to release its next quarterly earnings announcement on Wednesday, October 13th 2021.#N#View our earnings forecast for Q BioMed.
How has Q BioMed's stock price been impacted by Coronavirus?
Q BioMed Inc. (OTCMKTS:QBIO) announced its earnings results on Wednesday, July, 14th. The company reported ($0.08) EPS for the quarter, topping analysts' consensus estimates of ($0.12) by $0.04. The company had revenue of $0.05 million for the quarter.#N#View Q BioMed's earnings history.
Who are some of Q BioMed's key competitors?
Q BioMed's stock was trading at $1.5728 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, QBIO shares have decreased by 46.0% and is now trading at $0.85.#N#View which stocks have been most impacted by COVID-19.
What other stocks do shareholders of Q BioMed own?
Some companies that are related to Q BioMed include Virpax Pharmaceuticals (VRPX), Graybug Vision (GRAY), Gain Therapeutics (GANX), NeuroBo Pharmaceuticals (NRBO), Celsion (CLSN), OncoSec Medical (ONCS), Lumos Pharma (LUMO), Aptorum Group (APM), Aravive (ARAV), Otonomy (OTIC), Moleculin Biotech (MBRX), Aptevo Therapeutics (APVO), Akari Therapeutics (AKTX), VYNE Therapeutics (VYNE) and Aeterna Zentaris (AEZS).#N#View all of QBIO's competitors..
What is Q Biomed?
Based on aggregate information from My MarketBeat watchlists, some companies that other Q BioMed investors own include NVIDIA (NVDA), Micron Technology (MU), Washington Trust Bancorp (WASH), Nokia (NOK), (CGC), Cisco Systems (CSCO), Inovio Pharmaceuticals (INO), Intel (INTC), OPKO Health (OPK) and AT&T (T).
What is value scorecard?
Q BioMed Inc. is a biomedical acceleration and development company. It focuses on licensing, acquiring, and providing resources to life sciences and healthcare companies. Q BioMed Inc. is based in New York.